The upper bound of the confidence interval indicates that participants with α-syn SAA positive LRRK2 PD may progress up to 1.5 points per year faster than their α-syn SAA negative counterparts, excluding any clinically meaningful difference over at least 3 years. This evidence concerns the gene LRRK2 and Parkinson disease.